CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNSP CNS Pharmaceuticals, Inc.

Post-Mkt 10-16 18:11:53 EDT

4.85

-0.33

-6.30%

盘后4.86

+0.01+0.19%

16:10 EDT

High5.00	Low4.65	Vol13.30K
Open4.98	D1 Closing5.18	Amplitude6.76%
Mkt Cap7.09M	Tradable Cap6.57M	Total Shares1.46M
T/O64.60K	T/O Rate0.98%	Tradable Shares1.35M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CNSP","market":"US","secType":"STK","nameCN":"CNS Pharmaceuticals, Inc.","latestPrice":4.851,"timestamp":1792180800000,"preClose":5.1771,"halted":0,"volume":13301,"hourTrading":{"tag":"盘后","latestPrice":4.86,"preClose":4.851,"latestTime":"16:10 EDT","volume":72,"amount":349.92,"timestamp":1792181404799,"change":0.009,"changeRate":0.001855,"amplitude":0},"delay":0,"changeRate":-0.06298893202758306,"floatShares":1354600,"shares":1461399,"eps":-23.1416,"marketStatus":"Post-Mkt","change":-0.3261,"latestTime":"10-16 18:11:53 EDT","open":4.98,"high":5,"low":4.65,"amount":64601,"amplitude":0.067605,"askPrice":6.25,"askSize":1,"bidPrice":4.26,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-23.1416,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1792195200000},"marketStatusCode":4,"adr":0,"listingDate":1573189200000,"exchange":"NASDAQ","adjPreClose":5.1771,"postHourTrading":{"tag":"盘后","latestPrice":4.86,"preClose":4.851,"latestTime":"16:10 EDT","volume":72,"amount":349.92,"timestamp":1792181404799,"change":0.009,"changeRate":0.001855,"amplitude":0},"volumeRatio":2.880251},"requestUrl":"/m/hq/s/CNSP","defaultTab":"news","newsList":[{"id":"2672123711","title":"CNS Pharmaceuticals Holds Annual Shareholder Meeting, Elects Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2672123711","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672123711?lang=en_us&edition=fundamental","pubTime":"2026-10-02 20:02","pubTimestamp":1790942552,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals holds annual shareholder meeting, elects directorsCNS Pharmaceuticals held its annual shareholder meeting on Sept. 30, 2026.Shareholders endorsed amendments to the 2020 Equity Plan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL6H49Xw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664851125","title":"CNS Pharma Targets Oncology, Neurology In-Licensing to Build New Therapy Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2664851125","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664851125?lang=en_us&edition=fundamental","pubTime":"2026-09-01 21:03","pubTimestamp":1788267828,"startTime":"0","endTime":"0","summary":"CNS Pharma targets oncology, neurology in-licensing to build new therapy pipelineCNS Pharmaceuticals outlined a strategy to build a pipeline in oncology or neurology, targeting assets with best-in-cla","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL4FM7VN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662700784","title":"CNS Pharmaceuticals Posts On-Demand Virtual Investor “Why Now” Webcast Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2662700784","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662700784?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:02","pubTimestamp":1787835743,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals posts on-demand Virtual Investor “Why Now” webcast presentationCNS Pharmaceuticals posted an on-demand video webcast tied to its Virtual Investor “Why Now” presentation.Management ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL3MNjnl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661160290","title":"CNS Pharmaceuticals Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2661160290","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661160290?lang=en_us&edition=fundamental","pubTime":"2026-08-22 05:18","pubTimestamp":1787347138,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals announces annual shareholder meetingCNS Pharmaceuticals will hold its annual shareholder meeting virtually on Sept. 30, 2026.Shareholders will vote to elect six directors, includin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL97J8qK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661686297","title":"Vertical Data Names Chris Downs Interim CFO, Replaces Christopher Creatura as Finance Chief","url":"https://stock-news.laohu8.com/highlight/detail?id=2661686297","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661686297?lang=en_us&edition=fundamental","pubTime":"2026-08-22 04:06","pubTimestamp":1787342808,"startTime":"0","endTime":"0","summary":"Vertical Data names Chris Downs interim CFO, replaces Christopher Creatura as finance chiefVertical Data appointed Chris Downs interim chief financial officer, effective Aug. 17, 2026.Downs will also ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL4LPF0Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VDTA","BK4007","CNSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660677624","title":"CNS Pharmaceuticals Director Michal Fisher Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2660677624","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660677624?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:00","pubTimestamp":1787058054,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals director Michal Fisher files initial beneficial ownership statementCNS Pharmaceuticals director Michal Fisher filed an initial Form 3 disclosure dated May 4, 2026.Disclaimer:This n","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLb5XVmh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660467764","title":"Vertical Data Names Chris Downs Interim CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2660467764","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660467764?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:00","pubTimestamp":1787058034,"startTime":"0","endTime":"0","summary":"Vertical Data names Chris Downs interim CFOVertical Data appointed Chris Downs as interim CFO effective Aug. 17, 2026, naming him principal financial officer and principal accounting officer.Downs is ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL4NR4Rz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","INFU","BK4007","VDTA","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972580","title":"CNS Pharmaceuticals Q2 Net Income USD -2.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972580?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nPLXNSB8BW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658297259","title":"CNS Pharmaceuticals Q2 EPS USD -0.37","url":"https://stock-news.laohu8.com/highlight/detail?id=2658297259","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658297259?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nPLXNSB8BW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972825","title":"CNS Pharmaceuticals Q2 FY26 Net Loss Widens 9% to $2.59 Million Year over Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972825","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972825?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:57","pubTimestamp":1786535840,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Q2 FY26 net loss widens 9% to $2.59 million year over yearCNS Pharmaceuticals posted a net loss of $2.59 million for the quarter ended June 30, 2026, widening 9% year over year.Ope","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLcj7SN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658956117","title":"CNS Pharmaceuticals Inc Expected to Post a Loss of 24 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658956117","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658956117?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:01","pubTimestamp":1786392119,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc <CNSP.OQ> expected to post a loss of24cents a share - Earnings PreviewCNS Pharmaceuticals IncCNSP.OQCNSP.Ois expected to  report resultson August 12  for the period ending June 30 2026LSEG's mean analyst estimate for CNS Pharmaceuticals Inc is for a loss of 24 cents per share.The one available analyst rating on the shares is \"buy\".The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for CNS Pharmaceuticals Inc is $10.00, about 85.9% above its last closing price of $5.38This summary was machine generated August 10 at 20:01 GMT.  All figures in US dollars unless otherwise stated.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N4471U1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636847030","title":"CNS Pharma director Faith L. Charles buys 7,100 shares for $34,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2636847030","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636847030?lang=en_us&edition=fundamental","pubTime":"2026-05-20 21:04","pubTimestamp":1779282248,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals director Faith L. Charles bought 7,100 common shares in an open-market purchase priced at USD 4.79 per share.Her direct holding rose to 7,100 shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL4lN1dh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"CNS Pharma director Faith L. Charles buys 7,100 shares for $34,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636867626","title":"CNS Pharmaceuticals Registers 9.79 Million Shares for Selling Holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2636867626","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636867626?lang=en_us&edition=fundamental","pubTime":"2026-05-20 05:32","pubTimestamp":1779226368,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals  on Tuesday filed a registration statement covering the resale of up to 9.79 million shares by selling stockholders.The resale includes 650,000 common shares and 9.14 million shares issuable upon exercise of prefunded warrants with a $0.001 exercise price and no expiration date.The company said it will not receive proceeds from the sales.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4135","BK4007","CNS","CNSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636862444","title":"CNS Pharmaceuticals files to sell 9.79M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2636862444","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636862444?lang=en_us&edition=fundamental","pubTime":"2026-05-20 05:01","pubTimestamp":1779224470,"startTime":"0","endTime":"0","summary":"16:57 EDT CNS Pharmaceuticals (CNSP) files to sell 9.79M shares of common stock for holders Published first on TheFly – the ultimate source for rea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-files-to-sell-9-79m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-files-to-sell-9-79m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4135","CNSP","CNS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635721251","title":"CNS Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635721251","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635721251?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:51","pubTimestamp":1778795463,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryCNS Pharmaceuticals Inc CNSP.OQ reported a quarterly adjusted loss of $7.30 per share for the quarter ended Mar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R2N5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635714712","title":"CNS Pharmaceuticals Q1 net loss widens to $4.94 million from year-ago quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2635714712","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635714712?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:56","pubTimestamp":1778759777,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals posted a net loss of $4.94 million for the quarter ended March 31, 2026, widening from $4.3 million a year earlier.Research and development expense rose to $3.54 million from $3.24 million, on higher professional expenses, headcount costs, drug manufacturing tied to TPI 287, and other items.General and administrative expense climbed to $1.43 million from $1.1 million, driven by higher legal and professional fees and insurance costs.Cash totaled $2.95 million at March 31, 2026, with a working capital deficit of $504,000.Strategy update in March pivoted focus toward developing therapies for serious diseases, including exploring out-licensing opportunities for legacy assets TPI 287 and Berubicin.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inve","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDLbtMYKn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634375762","title":"CNS Pharmaceuticals Inc  expected to post a loss of $5.37 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634375762","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634375762?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:12","pubTimestamp":1778530324,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc  expected to post a loss of $5.37 a share - Earnings Preview CNS Pharmaceuticals Inc CNSP.OQ CNSP.O is expected to  report resultson May 13 (estimated) for the period ending Ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O2FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633746137","title":"What's Going On With CNS Pharmaceuticals Stock On Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2633746137","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633746137?lang=en_us&edition=fundamental","pubTime":"2026-05-06 21:51","pubTimestamp":1778075460,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals plans a pivot to an acquisition-led strategy, capital raise, and technicals signal momentum with caution.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/05/06/Medical-Research-And-Development-Center-.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/05/06/Medical-Research-And-Development-Center-.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/05/52323068/whats-going-on-with-cns-pharmaceuticals-stock-on-wednesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/05/52323068/whats-going-on-with-cns-pharmaceuticals-stock-on-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["CNS","BK4150","BK4007","CNSP","RSI","BK4217","SMA","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633508479","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2633508479","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633508479?lang=en_us&edition=fundamental","pubTime":"2026-05-05 01:59","pubTimestamp":1777917556,"startTime":"0","endTime":"0","summary":"Celcuity  reported late Friday positive topline results from a cohort of its phase 3 Viktoria-1 trial, with the study meeting its primary endpoint and showing a clinically meaningful improvement in progression-free survival.The study evaluated gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer who had progressed after a CDK4/6 inhibitor and an aromatase inhibitor.Shares jumped more than 16%, with intraday trading volume at over 2.5 million from a daily average of roughly 737,000.CNS Pharmaceuticals  shares surged 268% amid heavy trading after the company said Monday it signed deals for a private placement financing likely to generate roughly $22.5 million.Intraday trading volume catapulted to over 78.4 million shares from a daily average of about 32,000.American Express Global Business Travel, which is operated by Global Business Travel Group , said Monday it has entered into a definitive agreemen","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CNSP","GBTG","CELC","BK4007","BK4139","BK4142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632593009","title":"Why Is CNS Pharmaceuticals Stock (CNSP) Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2632593009","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632593009?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:58","pubTimestamp":1777903125,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals stock underwent a massive rally alongside a $22.5 million private placement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-cns-pharmaceuticals-stock-cnsp-up-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-cns-pharmaceuticals-stock-cnsp-up-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4135","CNSP","CNS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cnspharma.com","stockEarnings":[{"period":"1week","weight":-0.0323},{"period":"1month","weight":-0.0917},{"period":"3month","weight":0.0272},{"period":"6month","weight":1.0382},{"period":"1year","weight":-0.4562},{"period":"ytd","weight":-0.0139}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.019},{"period":"3month","weight":0.0383},{"period":"6month","weight":0.0868},{"period":"1year","weight":0.1603},{"period":"ytd","weight":0.1318}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.159728},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.133209},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.211644},{"month":4,"riseRate":0.285714,"avgChangeRate":0.005243},{"month":5,"riseRate":0.428571,"avgChangeRate":0.190802},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.167826},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.175954},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.097925},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.1054},{"month":10,"riseRate":0.142857,"avgChangeRate":0.03983},{"month":11,"riseRate":0.5,"avgChangeRate":-0.052563},{"month":12,"riseRate":0.142857,"avgChangeRate":-0.198237}],"exchange":"NASDAQ","name":"CNS Pharmaceuticals, Inc.","nameEN":"CNS Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CNS Pharmaceuticals, Inc.(CNSP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CNS Pharmaceuticals, Inc.,CNSP,CNS Pharmaceuticals, Inc.股票,CNS Pharmaceuticals, Inc.股票老虎,CNS Pharmaceuticals, Inc.股票老虎国际,CNS Pharmaceuticals, Inc.行情,CNS Pharmaceuticals, Inc.股票行情,CNS Pharmaceuticals, Inc.股价,CNS Pharmaceuticals, Inc.股市,CNS Pharmaceuticals, Inc.股票价格,CNS Pharmaceuticals, Inc.股票交易,CNS Pharmaceuticals, Inc.股票购买,CNS Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CNS Pharmaceuticals, Inc.(CNSP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}